In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewRecent Advances in Antiviral Therapy for Chronic Hepatitis CDirect anti-HCV agentsNew treatments for genotype 1 chronic hepatitis C - focus on simeprevirHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyFuture classes of hepatitis C virus therapeutic agentsIn-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 proteaseDevelopment of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsDrug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor bindingMolecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A ProteaseThe Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsMolecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of ResistancePreclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseSupplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini ReviewProbing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinaseHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsSimilar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankApplications of computer-aided approaches in the development of hepatitis C antiviral agents.Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataOnce-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Hepatitis C virus NS3 mutations in haemophiliacsMK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionHepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 culturesAntiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevirPre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirEfficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.
P2860
Q24628717-83876038-1404-451A-8AD5-EF80919D5762Q26750476-E86F25DA-2403-4BFE-AD42-0564809381F6Q26767329-F1B7DBB9-246C-4FF4-AECE-32FD83BB5380Q26853138-1AAC1E08-3AE7-4986-8568-7A0EF32933C4Q26853500-473F1128-C6EB-4B04-844B-E186E8B56BBAQ27009321-8BA66D6B-4D32-4B43-9261-8F85799AD66AQ27468875-39AA786F-04EE-40E8-B50A-C778C4211FE9Q27468990-33DE216C-B4D6-4B5E-8FB8-73848B56D4B8Q27665956-73B2503E-B811-46A2-81FA-6115A37089E5Q27667503-206F0DE7-A59E-4757-8312-C5FE7F8706F1Q27671640-3C4F2C57-4B97-49DD-8EAC-53CBFED634E0Q27675615-9A242617-2C2C-4564-9895-89896ACF3FAFQ27679235-0B92F3E0-F4C7-40B3-B7B2-1561A274810EQ28068362-4CF230B9-256D-4D76-BCB0-75EDE1CA5057Q28480947-17B00873-1FFD-4B6F-ACD7-E484E1BE55D6Q28481038-2310D890-28EE-4D63-8E54-33E1AC411C5EQ28538891-E1DFAD9D-A210-42ED-9666-90F6B8E062D8Q28542443-4D4C42B3-1605-4599-8085-8BAAEB4BBCF4Q28552134-4310724B-E6E4-4F64-B504-CE6B2B611F3EQ28552269-A72FC1FA-1EC4-4D69-98E3-103EFF90A7FDQ28553430-52931EAF-5B2A-41F6-B38C-689217442294Q30238530-08B2C27C-AC93-4417-BE5A-477D6CBB7F72Q30301355-3FCAF2CF-5029-465A-92AA-5B2570544881Q31042796-94E44C51-1ADB-4D71-8292-892D903C3D60Q33956796-704A09A8-DAAC-4D42-9EC0-AB089E46139AQ34057584-3BC7555A-FC25-44B8-A0FD-BBE91DCB4575Q34111759-A5582F8E-7E1E-4ABC-9247-C4CFE22BA5FAQ34276394-BD204AE1-86AF-4B4F-ADFD-CB11BFF57059Q34298877-A98EC22C-9E4D-4256-AA3B-2C0C0816F9D4Q34766299-56A08B60-D8D3-4222-9898-13B8F55434EBQ35139538-1CF60C69-3F24-4926-A5D0-88EF9303E28AQ35154587-D1C513BF-FB0B-4B51-9A0F-2D854038AEE6Q35757761-97A13B9E-E3F5-479D-ADC6-A0EE9A8A6D5EQ35759025-FE7517F1-D829-421C-A489-04D39878F580Q35867385-52F3BF4E-0ADA-4740-8C67-54A664B7EDC9Q35880497-ED9F34F5-4686-4350-B60B-3AFC8846A3D1Q36086454-A33A2500-9F44-458C-BA99-D8D94DB2B595Q36182240-AEB35920-4FE9-49EB-B5CE-CC0E00AED182Q36276803-633C8544-9662-4436-81BD-6294DE1CA72DQ36276817-259FA220-4BBE-4F31-AC69-467E57566317
P2860
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@en
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@nl
type
label
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@en
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@nl
prefLabel
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@en
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@nl
P2093
P2860
P356
P1476
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
@en
P2093
Annick Scholliers
Els Fransen
Gregory C Fanning
Herman de Kock
Jan Martin Berke
Jimmy Lindberg
Katrien Vermeiren
Kenneth A Simmen
Leen Vijgen
Lotta Vrang
P2860
P304
P356
10.1128/AAC.01452-09
P407
P577
2010-02-22T00:00:00Z